ExpreS2ion Biotechnologies Revenue and Competitors

ExpreS2ion Biotechnologies is a Denmark based biotech company specialised in the development of new vaccines and immunotherapy products. The company has a discovery platform built around a proprietary recombinant expression system, ExpreS2(TM), invented especially for fast and efficient development and production of complex proteins required for innovative new vaccines, immunotherapy and diagnostics. The system also includes functionally modified glycosylation variants. The Company develops vaccines and related products through collaborations and grants as well as it offers products, services and licences. The ExpreS2 platform has proven to be particular efficient for difficult-to-express proteins, as e.g. malaria antigens. This is documented by several malaria vaccines in development, of which two reported successful results from clinical phase 2a and 1a trials in 2018/19. Since founded in 2010, ExpreS2ion has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with a high number of leading research institutions, biotech and pharma companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops vaccines and immunotherapy products based on a novel plug-&-play VLP platform through its joint venture AdaptVac that was founded in 2017. The initial pipeline targets human cancer and cardiovascular diseases as well as some veterinary projects. ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary and operational unit of ExpreS2ion Biotech Holding AB, listed on Nasdaq first North, Stockholm (Ticker: EXPRS2).